[⁶⁸Ga]PSMA-HBED-CC PET/CT to differentiate between diffuse bone metastases of prostate cancer and osteopoikilosis

• References

• 1 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the ⁶⁸Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
• 2 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med 2015; 56: 668-674.
• 3 Heidenreich A, Bastian PJ, Bellmunt J. et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-137.
• 4 Tong EC, Samii M, Tchang F. Bone imaging as an aid for the diagnosis of osteopoikilosis. Clin Nucl Med 1988; 13: 816-819.
• 5 Verburg FA, Pfister D, Heidenreich A. et al. Extent of disease in recurrent prostate cancer determined by [⁶⁸Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2016; 43: 397-403.